- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- docetaxel, cisplatin, radiation treatment
- Drug · Procedure
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Rochester, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1009–1032
of 1,758
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Nivolumab, Ipilimumab, Carboplatin, Paclitaxel, Pemetrexed
- Drug
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Hackensack, New Jersey • Neptune City, New Jersey
- Conditions
- Metastatic Squamous Non-Small Cell Lung Cancer, Metastatic Nonsquamous Non-Small Cell Lung Cancer
- Interventions
- Retifanlimab, Placebo, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, nab-Paclitaxel
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 583 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 3
- States / cities
- Anaheim, California • Whittier, California • Reading, Pennsylvania
- Conditions
- Breast Cancer
- Interventions
- filgrastim, anastrozole, carboplatin, cisplatin, cyclophosphamide, etoposide, thiotepa, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2004
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Muscle Invasive Bladder Cancer
- Interventions
- Durvalumab, Cisplatin, Gemcitabine
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 1,063 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more
- Conditions
- Endometrial Cancer, Malignant Solid Tumour
- Interventions
- Puxitatug Samrotecan, Doxorubicin, Paclitaxel
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 69
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 60 more
- Conditions
- Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
- Interventions
- Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC, Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab, Docetaxel
- Biological · Drug
- Lead sponsor
- Genelux Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 15
- States / cities
- Bullhead City, Arizona • Clermont, Florida • Coral Springs, Florida + 11 more
- Conditions
- Extramedullary Plasmacytoma, Isolated Plasmacytoma of Bone, Light Chain Deposition Disease, Primary Systemic Amyloidosis, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Interventions
- dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide, bortezomib, thalidomide, melphalan, autologous stem cell transplant
- Drug · Procedure
- Lead sponsor
- Margarida Magalhaes-Silverman
- Other
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Head and Neck Cancer
- Interventions
- carboplatin, cisplatin, docetaxel, fluorouracil
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 14
- States / cities
- La Jolla, California • Denver, Colorado • Boca Raton, Florida + 11 more
- Conditions
- Adenocarcinoma of the Esophagus, Recurrent Esophageal Cancer, Stage IV Esophageal Cancer
- Interventions
- triapine, cisplatin
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Laryngeal Cancer
- Interventions
- AT-101, Docetaxel, Cisplatin, Carboplatin
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Squamous Cell Carcinoma
- Interventions
- Azacitidine, Cisplatin
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Brain and Central Nervous System Tumors, Neuroblastoma, Retinoblastoma, Sarcoma
- Interventions
- filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, leucovorin calcium, methotrexate, temozolomide, thiotepa, vincristine sulfate, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- Up to 10 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 17
- States / cities
- Honolulu, Hawaii • Scarborough, Maine • Grand Rapids, Michigan + 11 more
- Conditions
- Stage III Intrahepatic Cholangiocarcinoma AJCC v7, Stage IIIA Gallbladder Cancer AJCC v7, Stage IIIB Gallbladder Cancer AJCC v7, Stage IVA Gallbladder Cancer AJCC v7, Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7, Stage IVB Gallbladder Cancer AJCC v7, Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7, Unresectable Extrahepatic Bile Duct Carcinoma, Unresectable Gallbladder Carcinoma
- Interventions
- Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Nab-paclitaxel
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Rochester, Minnesota • Houston, Texas
- Conditions
- Small Cell Lung Cancer (SCLC)
- Interventions
- Pembrolizumab, Cisplatin, Carboplatin, Etoposide, Radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Platinum-Sensitive Ovarian Cancer, Ovarian Cancer
- Interventions
- Rina-S, Bevacizumab, Carboplatin, Gemcitabine, Paclitaxel, PLD
- Biological · Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 688 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 7
- States / cities
- Duarte, California • Danbury, Connecticut • Tigard, Oregon + 4 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Abemaciclib, Erlotinib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 453 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 54
- States / cities
- Fayetteville, Arkansas • Jonesboro, Arkansas • Duarte, California + 39 more
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Interventions
- Paclitaxel,, Bevacizumab, Cisplatin, Olaparib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 5
- States / cities
- Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 2 more
- Conditions
- Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8
- Interventions
- Biospecimen Collection, Cisplatin, Computed Tomography, Fluorouracil, Gemcitabine, Magnetic Resonance Imaging, Mitomycin, Pembrolizumab, Questionnaire Administration, Radiation Therapy
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 145
- States / cities
- Tucson, Arizona • Fayetteville, Arkansas • Rogers, Arkansas + 103 more
- Conditions
- Ganglioneuroblastoma, Nodular, Neuroblastoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dinutuximab, Doxorubicin, Echocardiography Test, Etoposide, FDG-Positron Emission Tomography and Computed Tomography Scan, Hematopoietic Cell Transplantation, Irinotecan, Isotretinoin, Leukapheresis, Magnetic Resonance Imaging, Melphalan, Multigated Acquisition Scan, Radiation Therapy, Radionuclide Imaging, Survey Administration, Temozolomide, Thiotepa, Topotecan, Tumor Resection, Vincristine
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 30 Years
- Enrollment
- 478 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 158
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 127 more
- Conditions
- Squamous Neck Carcinoma of the Head and Neck Cancer (SCCHN)
- Interventions
- Tirapazamine, Cisplatin, 5-fluorouracil, Radiotherapy (RT)
- Drug · Radiation
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 17 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2005
- U.S. locations
- 2
- States / cities
- Palo Alto, California • Stanford, California
- Conditions
- Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma, Childhood Mixed Cellularity Classical Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Childhood Nodular Sclerosis Classical Hodgkin Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
- Interventions
- Bleomycin Sulfate, Cisplatin, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Involved-Field Radiation Therapy, Prednisone, Vincristine Sulfate Liposome
- Biological · Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 1,734 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 153
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 127 more
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- Niraparib + Nivolumab, Niraparib + Ipilimumab
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Endometrial Cancer
- Interventions
- BNT323/DB-1303, Doxorubicin, Paclitaxel, Docetaxel
- Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 22
- States / cities
- Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 19 more